IL6 and cancer: The HALLMARK enrichment term showed that CXCL11 expression was positively associated with processes including complement, IL6-JAK-STAT3 signaling, inflammatory response, interferon-α response, interferon-γ response, allograft rejection, TNF-a signaling via NF-κb, and IL2-STAT5 signaling in most of the cancers we analyzed.